TY - JOUR
T1 - Systematic review and network meta-analysis of interventions for fibromyalgia
T2 - a protocol.
AU - Busse, Jason W.
AU - Ebrahim, Shanil
AU - Connell, Gaelan
AU - Coomes, Eric A.
AU - Bruno, Paul
AU - Malik, Keshena
AU - Torrance, David
AU - Ngo, Trung
AU - Kirmayr, Karin
AU - Avrahami, Daniel
AU - Riva, John J.
AU - Struijs, Peter
AU - Brunarski, David
AU - Burnie, Stephen J.
AU - LeBlanc, Frances
AU - Steenstra, Ivan A.
AU - Mahood, Quenby
AU - Thorlund, Kristian
AU - Montori, Victor M.
AU - Sivarajah, Vishalini
AU - Alexander, Paul
AU - Jankowski, Milosz
AU - Lesniak, Wiktoria
AU - Faulhaber, Markus
AU - Bała, Małgorzata M.
AU - Schandelmaier, Stefan
AU - Guyatt, Gordon H.
N1 - Funding Information:
This systematic review is funded by a Canadian Institutes of Health Research Knowledge Synthesis Grant. The development of this protocol was funded in-part by a grant from the Ontario Chiropractic Association. JWB is supported by a New Investigator Award from the Canadian Institutes of Health Research and Canadian Chiropractic Research Foundation. SE is supported by a Canadian Institutes of Health Research Doctoral Award. JJR is supported by an award from the NCMIC Foundation.
PY - 2013
Y1 - 2013
N2 - Fibromyalgia is associated with substantial socioeconomic loss and, despite considerable research including numerous randomized controlled trials (RCTs) and systematic reviews, there exists uncertainty regarding what treatments are effective. No review has evaluated all interventional studies for fibromyalgia, which limits attempts to make inferences regarding the relative effectiveness of treatments. We will conduct a network meta-analysis of all RCTs evaluating therapies for fibromyalgia to determine which therapies show evidence of effectiveness, and the relative effectiveness of these treatments. We will acquire eligible studies through a systematic search of CINAHL, EMBASE, MEDLINE, AMED, HealthSTAR, PsychINFO, PapersFirst, ProceedingsFirst, and the Cochrane Central Registry of Controlled Trials. Eligible studies will randomly allocate patients presenting with fibromyalgia or a related condition to an intervention or a control. Teams of reviewers will, independently and in duplicate, screen titles and abstracts and complete full text reviews to determine eligibility, and subsequently perform data abstraction and assess risk of bias of eligible trials. We will conduct meta-analyses to establish the effect of all reported therapies on patient-important outcomes when possible. To assess relative effects of treatments, we will construct a random effects model within the Bayesian framework using Markov chain Monte Carlo methods. Our review will be the first to evaluate all treatments for fibromyalgia, provide relative effectiveness of treatments, and prioritize patient-important outcomes with a focus on functional gains. Our review will facilitate evidence-based management of patients with fibromyalgia, identify key areas for future research, and provide a framework for conducting large systematic reviews involving indirect comparisons.
AB - Fibromyalgia is associated with substantial socioeconomic loss and, despite considerable research including numerous randomized controlled trials (RCTs) and systematic reviews, there exists uncertainty regarding what treatments are effective. No review has evaluated all interventional studies for fibromyalgia, which limits attempts to make inferences regarding the relative effectiveness of treatments. We will conduct a network meta-analysis of all RCTs evaluating therapies for fibromyalgia to determine which therapies show evidence of effectiveness, and the relative effectiveness of these treatments. We will acquire eligible studies through a systematic search of CINAHL, EMBASE, MEDLINE, AMED, HealthSTAR, PsychINFO, PapersFirst, ProceedingsFirst, and the Cochrane Central Registry of Controlled Trials. Eligible studies will randomly allocate patients presenting with fibromyalgia or a related condition to an intervention or a control. Teams of reviewers will, independently and in duplicate, screen titles and abstracts and complete full text reviews to determine eligibility, and subsequently perform data abstraction and assess risk of bias of eligible trials. We will conduct meta-analyses to establish the effect of all reported therapies on patient-important outcomes when possible. To assess relative effects of treatments, we will construct a random effects model within the Bayesian framework using Markov chain Monte Carlo methods. Our review will be the first to evaluate all treatments for fibromyalgia, provide relative effectiveness of treatments, and prioritize patient-important outcomes with a focus on functional gains. Our review will facilitate evidence-based management of patients with fibromyalgia, identify key areas for future research, and provide a framework for conducting large systematic reviews involving indirect comparisons.
UR - http://www.scopus.com/inward/record.url?scp=84885896117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885896117&partnerID=8YFLogxK
U2 - 10.1186/2046-4053-2-18
DO - 10.1186/2046-4053-2-18
M3 - Review article
C2 - 23497523
AN - SCOPUS:84885896117
SN - 1931-857X
VL - 2
SP - 18
JO - Unknown Journal
JF - Unknown Journal
M1 - 18
ER -